Vycor Medical (VYCO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 28, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VYCO SEC filings page.
Vycor Medical Inc (VYCO) reported $1.9M in revenue for fiscal year 2025, up 17.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is growing, but rising production costs and a liability-heavy balance sheet keep the business near break-even and cash-sensitive.
Revenue reached$1.86M in FY2025, but operating cash flow moved from$60K in FY2024 to-$13K in FY2025. The accompanying gross-margin contraction of5.7 pp means higher sales were not converting into cash as efficiently, weakening earnings quality. The reversal from positive cash generation to a cash outflow makes the cash trend more informative than the near-break-even operating result.
Liabilities were
Operating income reached
Financial Health Signals
We do not publish a peer-relative financial health score for Vycor Medical Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Vycor Medical Inc scores -60.23, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $33.6M against total assets of $830K. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Vycor Medical Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
Vycor Medical Inc reported a net loss of $72K while operations used $13K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Vycor Medical Inc generated $418K in revenue in Q2 2026. This represents a decrease of 15.7% from the same quarter a year earlier. Against the prior quarter it is down 8.8%.
Vycor Medical Inc's EBITDA was $22K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 67.1% from the same quarter a year earlier. Against the prior quarter it is down 63.6%.
Vycor Medical Inc reported a net loss of $22K in Q2 2026. This represents a decrease of 193.3% from the same quarter a year earlier. Against the prior quarter it is down 210.8%.
Vycor Medical Inc earned $0.00 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Vycor Medical Inc held $159K in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Vycor Medical Inc's gross margin was 82.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.
Vycor Medical Inc's operating margin was 1.6% in Q2 2026, reflecting core business profitability. This is down 8.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.3 percentage points.
Vycor Medical Inc's net profit margin was -5.3% in Q2 2026, showing the share of revenue converted to profit. This is down 10.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 9.7 percentage points.
Not reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
VYCO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $418K-15.7% | $459K+5.1% | $417K-8.4% | $514K+31.5% | $496K+22.2% | $436K+29.5% | $455K+47.7% | $391K+26.7% |
| Cost of Revenue | $74K-9.0% | $83K+7.1% | $82K+40.9% | $62K+68.1% | $81K+130.6% | $78K+110.4% | $58K+37.7% | $37K+13.8% |
| Gross Profit | $344K-17.1% | $375K+4.6% | $335K-15.6% | $452K+27.6% | $415K+11.9% | $359K+19.5% | $397K+49.3% | $354K+28.2% |
| R&D Expenses | N/A | N/A | $0-100.0% | N/A | $4K+85.6% | $6K | $7K+195.0% | $6K-11.4% |
| SG&A Expenses | $323K-6.5% | $315K-10.1% | $357K+0.1% | $405K+10.1% | $345K+2.1% | $351K+19.0% | $357K+13.7% | $368K+31.3% |
| Operating Income | $7K-86.6% | $46Kn/m | -$37K-288.8% | $32Kn/m | $51K+216.1% | -$13Kn/m | $19Kn/m | -$35Kn/m |
| EBITDA | $22K-67.1% | $60K+2782.7% | -$22K-163.2% | $47Kn/m | $66K+112.6% | $2K-61.2% | $34Kn/m | -$20Kn/m |
| Net Income | -$22K-193.3% | $20Kn/m | -$63Kn/m | $5Kn/m | $24Kn/m | -$39Kn/m | -$7Kn/m | -$60Kn/m |
| EPS (Basic) | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | -$0.01n/m | $0.00n/m | -$0.01n/m |
| EPS (Diluted) | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | -$0.01n/m | $0.00n/m | -$0.01n/m |
| Diluted Shares (Avg) | 33M-13.7% | 33M0.0% | N/A | 33M+1.4% | 39M+18.5% | 33M+2.3% | N/A | 33M+0.8% |
Not reported in any period shown, so not listed: Interest Expense, Income Tax.
VYCO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $813K-7.5% | $854K-9.2% | $830K-16.8% | $941K-12.4% | $879K-11.8% | $941K-2.9% | $998K+0.6% | $1.1M+1.9% |
| Current Assets | $636K+14.7% | $651K+8.4% | $563K-9.1% | $663K-10.9% | $554K-13.9% | $601K+2.1% | $620K+6.1% | $743K+18.8% |
| Cash & Equivalents | $159K+59.4% | $174K+184.4% | $87K-17.7% | $64K-59.3% | $100K-16.4% | $61K+39.2% | $106K+84.4% | $158K+128.3% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $191K+22.1% | $182K+3.1% | $159K+9.0% | $167K-10.8% | $156K-28.5% | $176K-20.5% | $146K-37.6% | $188K-8.4% |
| Accounts Receivable | $202K-0.1% | $194K-15.4% | $219K-10.8% | $326K+36.6% | $203K-19.8% | $229K-6.0% | $245K+14.0% | $239K-6.5% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $5.1M+6.7% | $5.1M+5.2% | $4.9M+4.9% | $5.0M+4.4% | $4.7M+4.9% | $4.8M+7.7% | $4.7M+8.6% | $4.8M+11.0% |
| Current Liabilities | $4.9M+7.6% | $4.9M+6.3% | $4.8M+6.3% | $4.8M+5.8% | $4.6M+6.4% | $4.7M+9.3% | $4.5M+10.4% | $4.6M+12.9% |
| Non-Current Liabilities | $134K-18.5% | $135K-24.2% | $136K-29.1% | $150K-26.7% | $164K-24.6% | $178K-22.8% | $192K-21.2% | $205K-19.8% |
| Total Equity | -$4.3Mn/m | -$4.2Mn/m | -$4.1Mn/m | -$4.0Mn/m | -$3.9Mn/m | -$3.9Mn/m | -$3.7Mn/m | -$3.7Mn/m |
| Retained Earnings | -$33.8Mn/m | -$33.8Mn/m | -$33.6Mn/m | -$33.6Mn/m | -$33.4Mn/m | -$33.5Mn/m | -$33.3Mn/m | -$33.2Mn/m |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
VYCO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5K-110.4% | $99Kn/m | $39Kn/m | -$72K-791.8% | $47K-45.8% | -$27K-1526.0% | -$38K-795.0% | $10Kn/m |
| Depreciation & Amortization | $15K0.0% | $14K-6.0% | $15K0.0% | $15K0.0% | $15K0.0% | $15K0.0% | $15K+3.5% | $15K+3.5% |
| Stock-Based Compensation | N/A | N/A | N/A | N/A | $0n/m | $18K+674.7% | N/A | $0-100.0% |
| Capital Expenditures | N/A | N/A | $2K | $1 | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | $38K | -$72K | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $342 | $2K | -$2K-1044.7% | $0n/m | N/A | N/A | $170n/m | -$5Kn/m |
| Financing Cash Flow | -$10Kn/m | -$15Kn/m | -$15Kn/m | $37K+12.3% | -$5Kn/m | -$18Kn/m | -$14Kn/m | $33K-4.7% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VYCO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.3%-1.3pp | 81.8%-0.3pp | 80.5%-6.8pp | 88.0%-2.6pp | 83.7%-7.7pp | 82.2%-6.9pp | 87.3%+0.9pp | 90.6%+1.1pp |
| Operating Margin | 1.6%-8.7pp | 10.0%+12.9pp | -8.8%-13.0pp | 6.2%+15.2pp | 10.3%+6.3pp | -2.9%-0.1pp | 4.3%+25.0pp | -9.0%-0.7pp |
| Net Margin | -5.3%-10.1pp | 4.4%+13.2pp | -15.0%-13.6pp | 1.0%+16.3pp | 4.8%+7.3pp | -8.8%+0.2pp | -1.5%+28.7pp | -15.3%+1.5pp |
| Return on Assets | -2.7%-5.5pp | 2.4%+6.5pp | -7.5%-6.9pp | 0.5%+6.1pp | 2.7%+3.7pp | -4.1%-0.9pp | -0.7%+8.7pp | -5.6%-0.6pp |
| Current Ratio | 0.130.0x | 0.130.0x | 0.120.0x | 0.140.0x | 0.120.0x | 0.130.0x | 0.140.0x | 0.160.0x |
| Asset Turnover | 0.51-0.1x | 0.54+0.1x | 0.500.0x | 0.55+0.2x | 0.56+0.2x | 0.46+0.1x | 0.46+0.1x | 0.36+0.1x |
| FCF Margin | N/A | N/A | 9.0% | -14.1% | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, Liabilities-to-Equity.
Note: Shareholder equity is negative (-$4.1M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.12), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Vycor Medical Inc VYCO | FY2025 | $1.9M | -$72K | -3.9% | $1.7M | — |
| CS Diagnostics Corp CSDX | FY2024 | N/A | $761 | N/A | $1.5M | — |
| Biotricity Inc BTCY | FY2026 | $16.0M | -$2.4M | -15.0% | $1.0M | — |
| REMSleep Holdings Inc RMSL | FY2025 | $17K | N/A | N/A | $2.5M | — |
| Odyssey Health Inc ODYY | FY2026 | N/A | N/A | N/A | $882K | — |
Where Vycor Medical Inc Ranks
Frequently Asked Questions
Vycor Medical Inc (VYCO) reported $1.9M in total revenue for fiscal year 2025. This represents a 17.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Vycor Medical Inc (VYCO) revenue grew by 17.2% year-over-year, from $1.6M to $1.9M in fiscal year 2025.
No, Vycor Medical Inc (VYCO) reported a net loss of $72K in fiscal year 2025, with a net profit margin of -3.9%.
Vycor Medical Inc (VYCO) had EBITDA of $93K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Vycor Medical Inc (VYCO) had a gross margin of 83.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Vycor Medical Inc (VYCO) had an operating margin of 1.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Vycor Medical Inc (VYCO) had a net profit margin of -3.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Vycor Medical Inc (VYCO) recorded an outflow of $19K in free cash flow during fiscal year 2025. This represents a -134.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Vycor Medical Inc (VYCO) recorded an outflow of $13K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Vycor Medical Inc (VYCO) had $830K in total assets as of fiscal year 2025, including both current and long-term assets.
Vycor Medical Inc (VYCO) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Vycor Medical Inc (VYCO) invested $10K in research and development during fiscal year 2025.
Vycor Medical Inc (VYCO) had a current ratio of 0.12 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Vycor Medical Inc (VYCO) had a return on assets of -8.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Vycor Medical Inc (VYCO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.7M as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Vycor Medical Inc (VYCO) trades at 1.0x sales, its market capitalization divided by $1.8M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.7M as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Vycor Medical Inc (VYCO) held $87K in cash, cash equivalents and investments, and reported an operating cash outflow of $13K over that year. Dividing the one by the other, the reported balance equals about 77 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Vycor Medical Inc (VYCO) has negative shareholder equity of -$4.1M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Vycor Medical Inc (VYCO) has an Altman Z-Score of -60.23, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Vycor Medical Inc (VYCO) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Vycor Medical Inc (VYCO) reported a net loss of $72K while operations used $13K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.